Company intelligence / Profile preview

Ivantis

Irvine, California, United Statesivantis.com ↗

Ownership: Private
Development stage: Commercial

Overview

Ivantis developed the Hydrus Microstent, a minimally invasive surgical implant for treating primary open-angle glaucoma. The Hydrus Microstent demonstrated strong clinical results in the HORIZON trial, with five-year data showing that about 65% of patients remained medication-free and over a 60% reduction in risk of secondary surgeries compared to cataract surgery alone. Over 85,000 devices have been implanted worldwide as of late 2021.

Therapeutic areas: Ophthalmology
Modalities: Device
Industry: Implantable Medical Devices

Drug pipeline

1 asset

Hydrus Microstent

Commercial

Indications: Open-angle glaucoma

Beyond the preview

Go deeper on Ivantis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ivantis.

Explore the full profile